These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12865399)

  • 1. Emergence of fluoroquinolone resistance among Bacteroides species.
    Golan Y; McDermott LA; Jacobus NV; Goldstein EJ; Finegold S; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Iannini P; Gorbach SL; Snydman DR
    J Antimicrob Chemother; 2003 Aug; 52(2):208-13. PubMed ID: 12865399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002).
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; Picazo JJ
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):221-3. PubMed ID: 16243476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece.
    Papaparaskevas J; Pantazatou A; Katsandri A; Houhoula DP; Legakis NJ; Tsakris A; Avlamis A
    J Antimicrob Chemother; 2008 Jul; 62(1):137-41. PubMed ID: 18385145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of newer quinolones against bacteroides group organisms.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein E; Finegold S; Harrell L; Hecht DW; Jenkins S; Pierson C; Venezia R; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3276-9. PubMed ID: 12234859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Golan Y; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Yu V; Rihs J; Gorbach SL
    Antimicrob Agents Chemother; 2007 May; 51(5):1649-55. PubMed ID: 17283189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.
    Snydman DR; Jacobus NV; McDermott LA; Ruthazer R; Goldstein EJ; Finegold SM; Harrell LJ; Hecht DW; Jenkins SG; Pierson C; Venezia R; Rihs J; Gorbach SL
    Clin Infect Dis; 2002 Sep; 35(Suppl 1):S126-34. PubMed ID: 12173121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of tigecycline against Bacteroides species.
    Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
    J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
    Ray GT; Baxter R; DeLorenze GN
    Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series.
    Slinger R; Desjardins M; McCarthy AE; Ramotar K; Jessamine P; Guibord C; Toye B
    BMC Infect Dis; 2004 Sep; 4():36. PubMed ID: 15380025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.
    Snydman DR; Jacobus NV; McDermott LA; Supran SE
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1710-2. PubMed ID: 10817736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates.
    Pumbwe L; Chang A; Smith RL; Wexler HM
    J Antimicrob Chemother; 2006 Sep; 58(3):543-8. PubMed ID: 16840432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducible metronidazole resistance in nim-positive and nim-negative bacteroides fragilis group strains after several passages metronidazole containing columbia agar plates.
    Schaumann R; Petzold S; Fille M; Rodloff AC
    Infection; 2005 Oct; 33(5-6):368-72. PubMed ID: 16258869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals.
    MacDougall C; Powell JP; Johnson CK; Edmond MB; Polk RE
    Clin Infect Dis; 2005 Aug; 41(4):435-40. PubMed ID: 16028149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae.
    Daporta MT; Muñoz Bellido JL; Guirao GY; Hernández MS; García-Rodríguez JA
    Int J Antimicrob Agents; 2004 Aug; 24(2):185-7. PubMed ID: 15288320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium.
    Bogaerts P; Berhin C; Nizet H; Glupczynski Y
    Helicobacter; 2006 Oct; 11(5):441-5. PubMed ID: 16961806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of nalidixic acid screening in fluoroquinolone-resistant typhoid salmonellae.
    Butt T; Khan MY; Ahmad RN; Salman M; Afzal RK
    J Coll Physicians Surg Pak; 2006 Jan; 16(1):31-4. PubMed ID: 16441985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
    Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
    Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.